Calamos Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Calamos Advisors LLC

$16.1 Billion
Q3 2024

A detailed history of Calamos Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Calamos Advisors LLC holds 45,244 shares of VRTX stock, worth $22.7 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

45,244

Previous 46,433 2.56%

Holding current value

$22.7 Million

Previous $21.8 Million 3.32%

% of portfolio

0.13%

Previous 0.14%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$460.0 - $505.78 $546,940 - $601,372	-1,189 Reduced 2.56%	45,244 $21 Million
Q2 2024 Jul 25, 2024	SELL	$392.81 - $485.53 $664,241 - $821,031	-1,691 Reduced 3.51%	46,433 $21.8 Million
Q1 2024 May 08, 2024	SELL	$407.69 - $446.08 $8.58 Million - $9.39 Million	-21,048 Reduced 30.43%	48,124 $20.1 Million
Q4 2023 Jan 31, 2024	SELL	$343.0 - $410.68 $316,589 - $379,057	-923 Reduced 1.32%	69,172 $28.1 Million
Q2 2023 Jul 28, 2023	SELL	$314.42 - $351.91 $3.61 Million - $4.04 Million	-11,477 Reduced 14.07%	70,095 $24.7 Million
Q1 2023 May 03, 2023	SELL	$283.23 - $323.1 $2.88 Million - $3.29 Million	-10,185 Reduced 11.1%	81,572 $25.7 Million
Q4 2022 Jan 25, 2023	SELL	$285.76 - $321.48 $4.62 Million - $5.2 Million	-16,171 Reduced 14.98%	91,757 $0
Q3 2022 Oct 24, 2022	BUY	$273.83 - $305.53 $10,131 - $11,304	37 Added 0.03%	107,928 $31.2 Million
Q2 2022 Aug 01, 2022	BUY	$234.96 - $292.55 $682,323 - $849,565	2,904 Added 2.77%	107,891 $30.4 Million
Q1 2022 May 03, 2022	BUY	$221.42 - $260.97 $3.06 Million - $3.61 Million	13,837 Added 15.18%	104,987 $27.4 Million
Q4 2021 Feb 01, 2022	SELL	$177.01 - $223.45 $3.51 Million - $4.43 Million	-19,807 Reduced 17.85%	91,150 $20 Million
Q3 2021 Oct 26, 2021	SELL	$181.39 - $202.99 $3.09 Million - $3.46 Million	-17,046 Reduced 13.32%	110,957 $20.1 Million
Q2 2021 Jul 22, 2021	SELL	$187.49 - $221.1 $13.4 Million - $15.8 Million	-71,266 Reduced 35.76%	128,003 $25.8 Million
Q1 2021 Apr 12, 2021	BUY	$207.02 - $241.31 $11.8 Million - $13.8 Million	57,190 Added 40.25%	199,269 $42.8 Million
Q4 2020 Jan 27, 2021	SELL	$207.01 - $276.09 $843,772 - $1.13 Million	-4,076 Reduced 2.79%	142,079 $33.6 Million
Q3 2020 Oct 26, 2020	SELL	$255.65 - $303.1 $6.59 Million - $7.82 Million	-25,789 Reduced 15.0%	146,155 $39.8 Million
Q2 2020 Jul 27, 2020	BUY	$225.48 - $295.8 $12.9 Million - $16.9 Million	57,288 Added 49.97%	171,944 $49.9 Million
Q1 2020 Apr 28, 2020	BUY	$199.77 - $247.81 $14.6 Million - $18.1 Million	72,931 Added 174.79%	114,656 $27.3 Million
Q4 2019 Jan 15, 2020	SELL	$166.71 - $223.91 $121,198 - $162,782	-727 Reduced 1.71%	41,725 $9.14 Million
Q3 2019 Oct 21, 2019	BUY	$166.23 - $187.09 $611,892 - $688,678	3,681 Added 9.49%	42,452 $7.19 Million
Q2 2019 Aug 07, 2019	BUY	$164.61 - $190.37 $317,368 - $367,033	1,928 Added 5.23%	38,771 $7.11 Million
Q1 2019 Apr 12, 2019	BUY	$163.73 - $194.7 $66,801 - $79,437	408 Added 1.12%	36,843 $6.78 Million
Q4 2018 Jan 24, 2019	BUY	$151.91 - $192.21 $828,669 - $1.05 Million	5,455 Added 17.61%	36,435 $6.04 Million
Q3 2018 Oct 22, 2018	SELL	$167.73 - $192.74 $528,014 - $606,745	-3,148 Reduced 9.22%	30,980 $5.97 Million
Q2 2018 Jul 17, 2018	BUY	$145.72 - $169.96 $586,960 - $684,598	4,028 Added 13.38%	34,128 $5.8 Million
Q1 2018 Apr 13, 2018	BUY	$151.6 - $177.13 $214,968 - $251,170	1,418 Added 4.94%	30,100 $4.91 Million
Q4 2017 Feb 13, 2018	SELL	$137.28 - $155.55 $75,092 - $85,085	-547 Reduced 1.87%	28,682 $4.3 Million
Q3 2017 Oct 25, 2017	BUY	$148.13 - $162.24 $151,388 - $165,809	1,022 Added 3.62%	29,229 $4.44 Million
Q2 2017 Aug 09, 2017	BUY	N/A	28,207	28,207 $3.64 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Vertex Pharmaceuticals Inc Transaction History